BeyondSpring Inc. BYSI
BeyondSpring Inc. (Nasdaq: BYSI) is an oncology drug developer. Its lead program, Plinabulin, is in Phase 3 for 2L/3L EGFR wild-type non-squamous NSCLC after progression on immune checkpoint inhibitors (with docetaxel). Its next catalyst on record is Plinabulin: Launch of confirmatory global Phase 3 study DUBLIN-4 (plinabulin + docetaxel vs docetaxel) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Plinabulin — Launch of confirmatory global Phase 3 study DUBLIN-4 (plinabulin + docetaxel vs docetaxel) (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Plinabulin + docetaxel (DUBLIN-3, completed; DUBLIN-4 confirmatory planned) | 2L/3L EGFR wild-type NSCLC | small molecule | Phase 3 |
| Plinabulin + nivolumab/ipilimumab (investigator-initiated) | 2L extensive-stage SCLC | small molecule | Phase 2 |
| Three small-molecule immune agents | oncology | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.